Climb Bio, Inc.(CLYM)Earnings, Financials & Key Ratios
CLYM•NASDAQ
$13.36
Price updated Jun 30, 2026
AboutClimb Bio, Inc., a biotechnology company, focuses on developing therapies for autoimmune-driven inflammatory diseases. It develops budoprutug, an anti-CD19 monoclonal antibody for various autoimmune diseases, including systemic lupus erythematosus and lupus nephritis, immune thrombocytopenia, and membranous nephropathy. The company was formerly known as Eliem Therapeutics, Inc. and changed its name to Climb Bio, Inc. in October 2024. Climb Bio, Inc. was incorporated in 2018 and is headquartered in Wilmington, Delaware.Show more
- Revenue$0
- EBITDA-$68M-123.3%
- Net Income-$60M+19.0%
- EPS (Diluted)-0.88+42.5%
- ROE-32.15%+30.5%
CLYM Price & Volume
Climb Bio, Inc. (CLYM) stock price & volume — 10-year historical chart
Loading chart...
Clinical Pivot Drives Sustained Capital Burn Risk
Investment Thesis • Updated 2026Q1
VerdictNegative
Growth:Contracting
Profitability:Negative
Financial:Vulnerable
Cash Flow:Burning
Primary Risk:Binary clinical trial failure
Key Thesis Takeaways
- Climb Bio is currently navigating a high-risk strategic transition following its pivot to the budoprutug asset, which has resulted in a significant contraction of its total asset base from $226.0 million in 2024Q2 to $152.4 million by 2026Q1.
- The company's reliance on non-revenue generating clinical development necessitates ongoing capital raises, as evidenced by the persistent quarterly operating losses exceeding $15 million.
- Investors should monitor the company's ability to reach critical Phase 2 milestones before its remaining $8.4 million cash position is exhausted, as the current trajectory suggests a high probability of further dilutive financing.
Verdict Logic
the company's cash position has plummeted from $223.1 million in 2024Q2 to just $8.4 million in 2026Q1, creating an unsustainable runway that poses a severe risk of near-term equity dilution.
CLYM Growth Metrics
Climb Bio, Inc. (CLYM) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM43.22%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM67.23%
Return on Capital
10 Years-46.48%
5 Years-38%
3 Years-40.58%
Last Year-36.4%
CLYM Recent Earnings
Climb Bio, Inc. (CLYM) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 3/12 qtrs (33%)
Q2 2026Latest
May 7, 2026Metric
Actual
Est
EPS
$0.20+23.1%
$0.26
Rev
—
—
Q2 2026
Mar 5, 2026Metric
Actual
Est
EPS
$0.26-30.0%
$0.20
Rev
—
—
Q4 2025
Nov 6, 2025Metric
Actual
Est
EPS
$0.19-18.8%
$0.16
Rev
—
—
Q3 2025
Aug 12, 2025Metric
Actual
Est
EPS
$0.13+31.6%
$0.19
Rev
—
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 7, 2026 | $0.20vs $0.26+23.1% | — |
| Q2 2026 | Mar 5, 2026 | $0.26vs $0.20-30.0% | — |
| Q4 2025 | Nov 6, 2025 | $0.19vs $0.16-18.8% | — |
| Q3 2025 | Aug 12, 2025 | $0.13vs $0.19+31.6% | — |
Based on last 12 quarters of dataView full earnings history →
Peers Comparison
Key metrics vs top competitors for Climb Bio, Inc. (CLYM)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $13.36 | $910.94M | -15.18 | — | — | -32.15% | — | |
| $38.51 | $7.91B | -13.90 | — | — | -68.16% | — | |
| $26.76 | $3.35B | -205.85 | 91.34% | -0.57% | -1.41% | — | |
| $21.53 | $2.22B | -20.70 | 20.6% | -67.85% | -23.43% | — | |
| $109.32 | $8.93B | -29.63 | -16.72% | -612.17% | -25.02% | — | |
| $350.06 | $10.11B | -25.97 | -100% | — | -43.02% | — |
Compare CLYM vs Peers
Climb Bio, Inc. (CLYM) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Get notified when CLYM posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
CLYM Frequently Asked Questions
Climb Bio, Inc. (CLYM) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Is CLYM profitable?
Climb Bio, Inc. (CLYM) reported a net loss of $52.8M for fiscal year 2025.
Dividend & Returns
What is CLYM's return on equity?
Climb Bio, Inc. (CLYM) has a return on equity (ROE) of -32.1%. Negative ROE indicates the company is unprofitable.
What is Climb Bio, Inc.'s free cash flow?
Climb Bio, Inc. (CLYM) had negative free cash flow of $53.5M in fiscal year 2025, likely due to heavy capital investments.